KX-826 (pyrilutamide) is first androgen receptor antagonist which has entered phase III clinical trial for male androgenetic alopecia treatment in China and global. Primary endpoint of KX-826 on male AGA patients met and demonstrated outstanding efficacy and safety profile. I've said before that if a suitable replacement came around and it was competitively priced, i would be eager to transition over to it, so what are your guys thoughts? Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Androgenetic Alopecia Was Met".

Pyrilutamide powder – RUdirect 99% Pyrilutamide powder – RUdirect

Hirshburg, J. M., Kelsey, P. A., Therrien, C. A., Gavino, A. C., & Reichenberg, J. S. (2016). Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic review. The Journal of clinical and aesthetic dermatology, 9(7), 56. Pyrilutamide (KX-826) is a topical androgen receptor (AR) antagonist, being developed as a potential topical treatment for androgenetic alopecia. The drug innovator is Kintor Pharmaceutical Limited, known for developing and commercializing innovative treatments for androgen receptor-related diseases like androgenetic alopecia, acne vulgaris, and certain cancers. Those on pyrilutamide 0.5% applied twice a day exhibited statistically significant improvement in total area hair count after six months of treatment. There was an increase of 22.73 hairs per cm 2, as opposed to the placebo group which had an increase of only 15.34 hairs per cm 2. Because of these results, 0.5% pyrilutamide solution was used in the phase 3 clinical trial. Pharma, K. (2022, August 3). KINTOR Pharma announces completion of patient enrollment in phase II clinical trial of KX-826 for treatment of Androgenetic Alopecia in the US. Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US. Retrieved October 1, 2022 .GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities. In terms of saving hair or regrowth, almost no treatment out there guarantees that. It just so happens we have anecdotal evidence that people using the "Big 3" of Finasteride, Minoxodil and Microneedling with perhaps a side of Nizoral containing 2% ketoconazole have shown regrowth. So there's a possibility this could help too but from a legal and marketing PoV, it's better to protect themselves by not saying that's a benefit of the product. The company said in the study KX-826 demonstrated clinically meaningful and statistically significant improvement in hair growth as measured by target area non-vellus hair count (TAHC). In addition, its safety profile was favorable.

Pyrilutamide - A Game Changer In the Making? - Hair Pyrilutamide - A Game Changer In the Making? - Hair

Results of Kintor’s Phase Ib Clinical Trials of Pyrilutamide in America, Kintor Pharmaceutical Limited (2022). Accessed online: https://en.kintor.com.cn/news/129.html

It's a game changer imo because as somebody above mentioned, people that can't tolerate Finasteride/Dutasteride orally or topically because of sides no longer have to worry about that issue and still have the ability to save their hair. Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry” Use PTSR and LOA information and event driven changes for your investment decisions to generate alpha

Pyrilutamide KX-826 | Ligand Chem, UK, Europe, America

Based on the data from clinical trials, pyrilutamide 0.5% solution has to be applied once daily for female AGA and twice daily for male AGA to get best results. Side effects of pyrilutamide Do you guys feel like we may even get some interesting combination treatments with people showing amazing results maybe even combining Finasteride and Pyrilutamide? PTSR and LoA scores are dynamic and are modified automatically with dynamic updates in drug, trials and company records. Time dependent variation is largely witnessed in the Clinical Trial attributes and influences the scores in positive or negative direction depending on its implication. This offers the user to examine the real time trajectory of clinical phase transition probability for a drug. For female pattern hair loss, only topical minoxidil is FDA-approved. However, both of these drugs have a few limitations and side effects. Hair transplantation works well but is expensive. Topical clascoterone 7.5% solution (Breezula) is another topical androgen receptor inhibitor undergoing clinical trials. Pyrilutamide’s mechanism of action

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this. PR Newswire. (2023, 28 March) Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China. Bloomberg.com. EQS Newswire. (2022, August 30). Kintor 2022 interim results: Pruxelutamide and KX-826 show positive results, business value has been presented. Bloomberg.com. Retrieved October 1, 2022. Solutions to hair loss have been coming and going for many MANY years. If all the promises companies have made over the years followed through, there would be no more balding in the world.